- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03663231
Duration of Effect of Biotene Spray in Patients With Dry Mouth
December 27, 2020 updated by: Ralph Saunders, University of Rochester
Duration of Effect of Biotene Spray in Patients With Symptomatic Dry Mouth
To determine the duration of effect of a single dose of Biotène Moisturizing Mouth Spray in subjects who complain of a clinically dry mouth.
The effect of the product will be compared to a control spray (water).
Study Overview
Study Type
Interventional
Enrollment (Actual)
37
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
Rochester, New York, United States, 14620
- University of Rochester Eastman Dental Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adults who are in good general health and reply initially affirmatively to the question, "Do you feel that your mouth is too dry and causes you discomfort at times during the day other than on awakening from sleep?" This question is an adaptation of the question used successfully by Jose and others (2016) to recruit study subjects.
- Adults who are able to communicate easily in English and who are able to demonstrate understanding of the study instructions.
- Adults who are physically able to perform an unstimulated whole saliva flow rate (UWSFR) test and who produce 0.2 mL/min or less of saliva.
Exclusion Criteria:
- Adults under the care of a health professional specifically for xerostomia treatment, including those taking prescription systemic parasympathetic medications.
- Adults who regularly "self-medicate" their xerostomia with water or other agents or products designed to treat their xerostomia and are unwilling or unable to cease use of the agent for at least 48 hours prior to the two test visits.
- Adults who are primarily mouth breathers (i.e. mouth breathing secondary to nasal obstruction)
- Adults who cannot consent for themselves or have physical/mental disabilities requiring a caregiver.
- Adults with a known allergy to any of the ingredients in Biotène Spray (eg. dairy allergy)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Biotene
People who present with dry mouth and will receive a single dose of Biotene.
|
Biotène Dry Mouth Moisturizing Spray contains water, polyglycitol, propylene glycol, sunflower oil, xylitol, milk protein extract, potassium sorbate, acesulfame K, potassium thiocyanate, lysozyme, lactoferrin, lactoperoxidase.
3 sprays, approximately 15 mL.
|
Placebo Comparator: Placebo
People who present with dry mouth and will receive a single dose of an alternative agent.
|
IND/IDE exempt device primarily water
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Duration of Action of Intervention
Time Frame: baseline up to 2 hours
|
Participant will receive a dose of Biotene or placebo (water) and will be asked if their mouth is dry up to 2 hrs.
The time at which their mouth becomes dry again will be the duration of action.
|
baseline up to 2 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Tolerability of Product
Time Frame: 2 hours
|
Subjects were asked to agree or disagree with the following statement where 1= strongly agree and 5- strongly disagree: The taste of the product was tolerable.
|
2 hours
|
Mean Acceptability of Product
Time Frame: 2 hours
|
Subjects were asked to agree or disagree with the following statement where 1= strongly agree and 5- strongly disagree: The thickness of the product was acceptable.
|
2 hours
|
Mean Continued Use of Project
Time Frame: 2 hours
|
Subjects were asked to agree or disagree with the following statement where 1= strongly agree and 5- strongly disagree: I would like to continue using this product.
|
2 hours
|
Mean Purchase Product Rating
Time Frame: 2 hours
|
Subjects were asked to agree or disagree with the following statement where 1= strongly agree and 5- strongly disagree: I would purchase this product to use on a regular basis.
|
2 hours
|
Mean Ease of Use of Product
Time Frame: 2 hours
|
Subjects were asked to agree or disagree with the following statement where 1= strongly agree and 5- strongly disagree: This product is easy to use.
|
2 hours
|
Mean Preference for Another Product
Time Frame: 2 hours
|
Subjects were asked to agree or disagree with the following statement where 1= strongly agree and 5- strongly disagree: I would prefer using another product.
|
2 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 11, 2019
Primary Completion (Actual)
November 22, 2019
Study Completion (Actual)
November 22, 2019
Study Registration Dates
First Submitted
August 8, 2018
First Submitted That Met QC Criteria
September 6, 2018
First Posted (Actual)
September 10, 2018
Study Record Updates
Last Update Posted (Actual)
January 20, 2021
Last Update Submitted That Met QC Criteria
December 27, 2020
Last Verified
December 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 69726
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dry Mouth
-
Maastricht University Medical CenterCompletedPatients of Advanced Age (≥ 70 Years) With a Clinical Diagnosis of Chronic Dry MouthNetherlands
-
Dow University of Health SciencesCompleted
-
Riyadh Colleges of Dentistry and PharmacyUnknownDry SocketSaudi Arabia
-
National University of MalaysiaCompletedXerostomia | Dry MouthMalaysia
-
Procter and GambleCompleted
-
Roxane LaboratoriesCompletedDry MouthUnited States
-
Roxane LaboratoriesCompleted
-
Procter and GambleCompletedDry MouthUnited States
-
University of KentuckyCompleted
Clinical Trials on Biotene
-
SunBio, Inc.NAMSA; RudacureCompleted
-
St George Hospital, AustraliaCompleted
-
University of IowaEnrolling by invitationEdentulous Jaw | Edentulous MouthUnited States
-
GlaxoSmithKlineCompletedXerostomiaUnited States
-
Unither Pharmaceuticals, FranceCompletedHead and Neck Cancer | Xerostomia | Hyposalivation | Sjögren SyndromeFrance
-
University of Southern CaliforniaWithdrawnOveractive Bladder | Xerostomia | Compliance
-
Nova Scotia Health AuthorityDalhousie UniversityUnknownXerostomia | Hyposalivation
-
GlaxoSmithKlineCompletedXerostomiaUnited States
-
GlaxoSmithKlineCompleted